Quest Diagnostics raised full-year 2026 adjusted diluted EPS guidance to $10.63-$10.83 from $10.50-$10.70 and lifted net revenue expectations to $11.78 billion-$11.90 billion from prior guidance. The update points to improved operating momentum and a modestly stronger outlook for the healthcare diagnostics company. This is constructive for the stock, though the move appears incremental rather than transformational.
Quest Diagnostics raised full-year 2026 adjusted diluted EPS guidance to $10.63-$10.83 from $10.50-$10.70 and lifted net revenue expectations to $11.78 billion-$11.90 billion from prior guidance. The update points to improved operating momentum and a modestly stronger outlook for the healthcare diagnostics company. This is constructive for the stock, though the move appears incremental rather than transformational.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.45
Ticker Sentiment
